Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

• ClinicalTrials.gov Identifier: NCT00161863
• Recruitment Status: Completed
• First Posted: September 13, 2005
• Last Update Posted: May 21, 2015
• Sponsor: Pfizer
• Information provided by: Pfizer

Tracking Information

• First Submitted Date: September 8, 2005
• First Posted Date: September 13, 2005
• Last Update Posted Date: May 21, 2015
• Study Start Date: September 2002
• Primary Completion Date: Not Provided
• Current Primary Outcome Measures: Not Provided
• Original Primary Outcome Measures: Not Provided
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
• Official Title: Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
• Brief Summary: The purpose of this study is to investigate the safety of five consecutive lots of FSME-IMMUN NEW in healthy volunteers. The main criterion for investigation is the fever rate after the first vaccination in three different age classes. The immunogenicity of 0.25 ml FSME-IMMUN NEW has been demonstrated in previous clinical studies in children; therefore, in the present study, immunogenicity was investigated in a subgroup only.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Prevention
• Condition: Tick-borne Encephalitis
• Intervention: Biological: FSME-IMMUN NEW 0.25 ml
• Study Arms: Not Provided
• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Enrollment: Not Provided
• Original Enrollment: Not Provided
• Study Completion Date: January 2003
• Primary Completion Date: Not Provided

Eligibility Criteria

Inclusion Criteria:

Male and female children and adolescents will be eligible for participation in this study if:

• they are aged 1 year (from the 1st birthday) to < 16 years (to the last day before the 16th birthday);
• they are clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial);
• their parents/legal guardians understand the nature of the study and agree to its provisions;
• written informed consent is available from both parents/legal guardians,
• for Germany/Austria: additional written informed consent is available for children older than 8 years
• they or their parents/legal guardians agree to keep a volunteer diary.

For safety reasons, female volunteers who have reached sexual maturity at study start have to meet the following additional inclusion criteria:

- negative pregnancy test at study entry;

Exclusion Criteria:

Children and adolescents will be excluded from participation in this study if they:

• have a history of any TBE vaccination;
• have a history of TBE infection;
• have a history of allergic reactions to one of the components of the vaccine;
• suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions;
• are known to be HIV positive (a special HIV test is not required for the purpose of the study);
• have received banked blood or immunoglobulins within one month of study entry;
• have a history of vaccination against yellow fever and/or Japanese B-encephalitis;
• suffer from hemorrhagic diathesis;
• are participating simultaneously in another clinical trial;
• if female: are pregnant or breastfeeding.

Volunteers who meet the inclusion/exclusion criteria, but have a febrile illness (body temperature > 38°C) at the scheduled time of vaccination, will not be vaccinated before their body temperature returns to normal.

Volunteers who have received any other vaccination within 4 weeks prior to visit 1 will not be vaccinated until an interval of 4 weeks has passed. In this case visit 1 will take place separately.

If volunteers have received antipyretics within 4 hours prior to the intended TBE vaccination, the vaccination should be performed at a later time.

Volunteers who have a positive TBE antibody value prior to the first vaccination will be excluded from the statistical analysis of the primary endpoint.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 1 Year to 15 Years (Child)
• Accepts Healthy Volunteers: Not Provided
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Austria, Germany, Poland

Administrative Information

• NCT Number: NCT00161863
• Other Study ID Numbers: 209
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Not Provided
• Original Responsible Party: Same as current
• Current Study Sponsor: Pfizer
• Original Study Sponsor: Baxter BioScience
• Collaborators: Not Provided

Investigators

• Principal Investigator: Baxter BioScience Investigator; Baxter BioScience

• PRS Account: Pfizer
• Verification Date: May 2015